Response to crizotinib in a patient with MET-amplified hepatocellular carcinoma.

Qinglian ChenChunfeng XieKunliang FengHaijun HuangChengming XiongTengjiao LinWenjing WangMian XuXianwei YangChong Zhong

Published in: Hepatology research : the official journal of the Japan Society of Hepatology (2021)

Our case report suggests NGS could help identify patients with high MET amplification in HCC who were likely to benefit from MET inhibitors; moreover, this requires further investigation in clinical trials.

Keyphrases

case report
tyrosine kinase
clinical trial
nucleic acid
epidermal growth factor receptor
advanced non small cell lung cancer
randomized controlled trial
open label